-
公开(公告)号：WO2021240531A1
公开(公告)日：2021-12-02
申请号：PCT/IN2020/050609
申请日：2020-07-15
发明人： NANDI, Indranil , JAIN, Anil , GAT, Ganesh Vinayak
IPC分类号： A61K9/20 , A61K31/53 , A61K31/683 , A61P31/12
摘要： Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.
-
公开(公告)号：WO2020070731A1
公开(公告)日：2020-04-09
申请号：PCT/IB2019/058517
申请日：2019-10-07
发明人： SOHI, Harmik , HASIJA, Rahul , MALIK, Basant , MEHTA, Kamal S. , KUMAR, Dinesh
摘要： The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to 99m Tc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with 99m Tc-pertechnetate solution gives stabilized 99m Tc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.
-
公开(公告)号：WO2019058354A1
公开(公告)日：2019-03-28
申请号：PCT/IB2018/057400
申请日：2018-09-25
摘要： The present invention relates to orally administered liquid pharmaceutical compositions of eslicarbazepine. The liquid compositions are in the form of ready to use suspension and suspension powder for reconstitution. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile and pH. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide physician with providing a more convenient and less cumbersome posology.
-
公开(公告)号：WO2018007956A1
公开(公告)日：2018-01-11
申请号：PCT/IB2017/054048
申请日：2017-07-05
发明人： SONI, Pankaj , NAKHAT, Premchand Dalichandji , GAT, Ganesh Vinayak , MEHTA, Kamal S , KUMAR, Dinesh , BALI, Vikas
IPC分类号： A61K31/41 , A61K31/4196 , A61K9/20 , A61P7/00
摘要： of the invention The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.
摘要翻译： 本发明涉及稳定的速释固体口服药物组合物，其包含铁螯合剂如Deferasirox和至少一种药学上可接受的赋形剂，其中所述组合物不含助流剂。 现有技术公开了各种技术挑战并提出了用于开发Deferasirox的速释剂型的限制性和复杂的解决方案，例如利用大量赋形剂或非常规制剂技术。 根据本发明制备的Deferasirox的不含助流剂的速释固体口服药物组合物显示出期望的技术属性，如药物稳定性，流动性和相当的溶解度，与参考列出的药物的生物等效性。
-
5.发明申请
公开(公告)号：WO2023007502A1
公开(公告)日：2023-02-02
申请号：PCT/IN2021/050829
申请日：2021-08-27
发明人： THOMAS, Saji , SHEKHAWAT, Rajendra , PRASAD, M. Umamaheshwar , BISWAS, Bidyut , CHAKRAVARTHY, Rohit , PATEL, Chetan Balubhai , LINGABHAT, Anilkumar Haribhat , SADASHIVAPPA, Mohan Chikmagalur , NANDI, Indranil
IPC分类号： C07D403/10 , A61K31/4178
摘要： The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities. More particularly, the present invention relates to process for the preparation of Losartan, Losartan potassium of Formula I or its other pharmaceutically acceptable salts thereof containing less than 10 ppm of each of the azido impurity, wherein azido impurity is selected from the group comprising of 5-(4'-(azidomethyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole, 4'-(azidomethyl)-[1,1'-biphenyl]-2-carbonitrile, 4'-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile, 5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole, 5-(azidomethyl)-2-butyl-4-chloro-1H-imidazole, 4'-((4-(azidomethyl)-2-5 butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile, 5-(4'-((4-(azidomethyl)-2-butyl-5-chloro-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole and 1-((1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl)-5-(4'-((5-(azidomethyl)-2-butyl-4-chloro-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H-tetrazole. More particularly, the present invention 0 relates to a simple, economical and industrially efficient process for the preparation of Losartan potassium of Formula I.
-
公开(公告)号：WO2021240543A1
公开(公告)日：2021-12-02
申请号：PCT/IN2021/050507
申请日：2021-05-25
发明人： NANDI, Indranil , MUKHERJEE, Tusharmouli , KUMAR, Dinesh , JAIN, Anil , SONI, Pankaj , MISTRY, Gaurav Navinbhai , JAISWAL, Nilesh
IPC分类号： A61K9/00 , A61K31/675
摘要： The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other 5 antiviral drugs. The present invention also relates to methods for preparing these transmucosal pharmaceutical compositions. Compositions prepared as per the present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions prepared as per the present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration, and dissolution. The compositions prepared as per the present 10 invention are useful in the treatment of viral infections including coronavirus infection (COVID-19).
-
公开(公告)号：WO2019058353A1
公开(公告)日：2019-03-28
申请号：PCT/IB2018/057398
申请日：2018-09-25
IPC分类号： A61K31/55
CPC分类号： A61K31/55 , A61K9/0095 , A61K9/5047
摘要： The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.
-
8.发明申请PHARMACEUTICAL SUSPENSION DOSAGE FORM OF BENZIMIDAZOLE COMPOUNDS AND PROCESS OF PREPARATION THEREOF 审中-公开苯并咪唑化合物的药物悬浮剂形式及其制备方法
公开(公告)号：WO2018065953A1
公开(公告)日：2018-04-12
申请号：PCT/IB2017/056183
申请日：2017-10-06
IPC分类号： C07D401/00 , A61K9/00 , A61K9/16 , A61K31/4439
摘要： The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.
摘要翻译： 本发明涉及适用于制备包含酸不稳定苯并咪唑化合物的悬浮液的固体口服药物剂型及其制备方法。 现有技术公开了与颗粒相关的各种技术挑战，用于重新形成悬浮液如颗粒的聚集，粘度和胶凝时间。 本发明的固体口服药物剂型在与含水介质混合时形成均匀的悬浮液，并表现出所需的技术属性，如粘度，药物释放，凝胶化时间，溶解和对鼻胃管和胃管的粘附性降低。
-
9.发明申请DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF PANTOPRAZOLE AND PROCESS FOR PREPARATION THEREOF 审中-公开泮托拉唑的延迟释放药物组合物及其制备方法
公开(公告)号：WO2018065952A1
公开(公告)日：2018-04-12
申请号：PCT/IB2017/056182
申请日：2017-10-06
发明人： MEHTA, Kamal Surendrakumar , SRIVASTAVA, Saurabh , KUMAR, Dinesh , JHA, Amit Kumar , MOHANTA, Subash Chandra , PANDA, Sunil Kumar , GAT, Ganesh Vinayak
IPC分类号： A61K31/4439 , A61K9/16 , A61K9/20 , A61K9/28
摘要： The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comrising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.
摘要翻译： 本发明公开了用于质子泵抑制剂化合物的口服悬浮液的稳定的延迟释放多颗粒粉末，其包含：a）具有有效量的质子泵抑制剂和至少一种或多种药物赋形剂的核心，b） 在核心上的至少一个水溶性密封涂层，c）在密封涂层上的至少一个肠溶衣层，其中所述核心包含崩解剂（0-10％）和/或表面活性剂（0-2％）w / w核心。 现有技术公开了限制性制剂技术并建议大量的各种赋形剂以达到所需的技术属性。 制备的测试制剂表现出期望的药物技术属性，例如药物释放，测定，稳定性，无多晶型变化，减少对鼻胃和美食管的粘连以及包装材料。
-
公开(公告)号：WO2016139683A3
公开(公告)日：2016-09-09
申请号：PCT/IN2016/050079
申请日：2016-03-04
发明人： JAIN, Rakesh , GAT, Ganesh Vinayak , NITHIYANANDAM, Ravikumar , PANDA, Rashmi Ranjan , KUMAR, Dinesh
IPC分类号： A61K31/496 , A61K31/194 , A61K45/06
摘要： The present invention relates to a solid oral pharmaceutical composition comprising Lurasidone or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof, wherein the composition is substantially free of binder. The invention further relates to processes for the preparation of such compositions comprising Lurasidone.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.01 秒)
